The article discusses potential therapeutic options for the 2019 novel coronavirus (2019-nCoV, now known as SARS-CoV-2). It emphasizes the urgent need for repurposing existing antiviral agents to treat 2019-nCoV, as no specific drugs or vaccines are currently available. The article reviews the potential of drugs already approved or in development for other viral infections, such as HIV, hepatitis B, hepatitis C, and influenza, based on their effectiveness against SARS and MERS. 2019-nCoV is an enveloped, positive-sense, single-stranded RNA beta-coronavirus. It encodes non-structural, structural, and accessory proteins, with key enzymes in its life cycle being potential targets for antiviral agents. The catalytic sites of these enzymes are highly conserved, suggesting that existing inhibitors for SARS and MERS may be effective against 2019-nCoV. Several antiviral agents are discussed, including nucleoside analogues like favipiravir, ribavirin, remdesivir, and galidesivir, which target the RNA-dependent RNA polymerase. Protease inhibitors such as lopinavir and ritonavir, originally developed for HIV, may inhibit the 3-chymotrypsin-like protease of 2019-nCoV. However, their effectiveness against coronavirus proteases is uncertain due to structural differences. The spike glycoprotein is another potential target, with Griffithsin, a lectin derived from red algae, showing activity against SARS-CoV spike glycoprotein. Host-targeted agents like interferon and chloroquine are also considered, with chloroquine showing inhibitory effects against 2019-nCoV in vitro. The article highlights the need for further clinical trials and optimization of existing antiviral agents to combat 2019-nCoV. It also emphasizes the importance of developing broad-spectrum antiviral agents to address future coronavirus outbreaks.The article discusses potential therapeutic options for the 2019 novel coronavirus (2019-nCoV, now known as SARS-CoV-2). It emphasizes the urgent need for repurposing existing antiviral agents to treat 2019-nCoV, as no specific drugs or vaccines are currently available. The article reviews the potential of drugs already approved or in development for other viral infections, such as HIV, hepatitis B, hepatitis C, and influenza, based on their effectiveness against SARS and MERS. 2019-nCoV is an enveloped, positive-sense, single-stranded RNA beta-coronavirus. It encodes non-structural, structural, and accessory proteins, with key enzymes in its life cycle being potential targets for antiviral agents. The catalytic sites of these enzymes are highly conserved, suggesting that existing inhibitors for SARS and MERS may be effective against 2019-nCoV. Several antiviral agents are discussed, including nucleoside analogues like favipiravir, ribavirin, remdesivir, and galidesivir, which target the RNA-dependent RNA polymerase. Protease inhibitors such as lopinavir and ritonavir, originally developed for HIV, may inhibit the 3-chymotrypsin-like protease of 2019-nCoV. However, their effectiveness against coronavirus proteases is uncertain due to structural differences. The spike glycoprotein is another potential target, with Griffithsin, a lectin derived from red algae, showing activity against SARS-CoV spike glycoprotein. Host-targeted agents like interferon and chloroquine are also considered, with chloroquine showing inhibitory effects against 2019-nCoV in vitro. The article highlights the need for further clinical trials and optimization of existing antiviral agents to combat 2019-nCoV. It also emphasizes the importance of developing broad-spectrum antiviral agents to address future coronavirus outbreaks.